Markets
boxing match
Getty Images

The Federal Reserve is playing rope-a-dope with inflation

Rolling with the pricing punches

Luke Kawa

Mike Tyson famously said, “Everyone has a plan until they get punched in the face.”

Surprisingly hot US inflation so far this year has been — at best — a gut punch to the Federal Reserve’s plan to deliver rate cuts this year to reduce its policy rate from the highest level in over two decades. At worst, it’s been a knockout blow.

Back in December, the central bank expected that core PCE inflation would decelerate from 2.8% to 2.4% over the course of this year. That forecast was raised in March to 2.6%. And with inflation having surprised to the upside since then, the risks are tilted toward another upward revision when the central bank updates its projections in June.

Markets have reacted strongly to the short-term resurgence of inflationary pressures. In January, traders were pricing over 170 basis points of easing from the US central bank this year; that has since receded to about 40 basis points. There has even been a creeping tendency to price the Federal Reserve’s next move as a hike: Options markets suggest roughly 15% odds of the Federal Reserve’s policy rate being higher than current levels around year-end. 

Faced with stubbornly high price pressures, Federal Reserve Chair Jerome Powell is signaling the central bank is still far from fighting fire with fire and aggressively punching back to attempt to slow the economy and inflation. Instead, he’s borrowing a tactic from another prominent pugilist: Muhammad Ali’s “rope-a-dope” strategy.

Basically? Take the hits, ride it out, wait until the opponent is exhausted.

The message is that the fight against inflation will be won over time without the need for further policy tightening.

5.25%-5.50%
“Unlikely that the next policy rate move will be a hike.”

Several times during his press conference, Powell was asked about what would make the Federal Reserve deliver rate hikes, rather than cuts, going forward. According to Powell, it’s “unlikely” that the Federal Reserve’s next move would be an interest-rate increase, and that the policy discussion inside the central bank is focused on how long to hold rates at this level (before lowering them).

The bad-news story of inflation in 2024 has also been accompanied by some more favorable developments: Economic growth has been more robust than anticipated. And while some labor-market metrics have cooled and are normalizing toward prepandemic levels, overall conditions in the job market remain strong by historical standards. Taken collectively, this suite of macroeconomic outcomes would suggest that policy rates above 5% may not be doing enough to cool economic activity and, in turn, inflation.

Powell is taking a much more benign view.

“The signal that we’re taking [from the data] is that it is likely to take longer for us to gain confidence that we are on a sustainable path back to 2% inflation,” Powell said, later adding: “My expectation is that we will, over the course of this year, see inflation move back down. That’s my forecast.”

Central bankers often say that they are “data-dependent” — and of course all reasonable people update their views when new information comes to light. But ultimately, monetary policymakers have to be outlook dependent and make decisions based on their expectations for how inflation, the labor market, and growth will evolve in the future, not just what’s happening now. That’s the message Powell is sending in not (over?)reacting strongly to the inflation data.

This strategy of weathering the storm when up against the ropes worked wonders for Muhammad Ali in 1974. Will inflation dynamics behave the same as George Foreman’s arms and just wear down? That’s an open question.

More Markets

See all Markets
markets

FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation

The Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 compounding, a day after Hims & Hers announced that it would sell copies ofNovo Nordisk’sWegovy pill.

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Airlines rise, continuing their volatile 2026, as US-Iran talks may foreshadow some oil supply relief

Airline stocks are surging on Friday, as the market appears to be pricing in some medium-term oil pricing relief following talks between the US and Iran. Iranian officials referred to the meeting as “a good beginning.”

Shares of budget carriers, which have tighter margins and are more sensitive to fluctuations in fuel costs, are leading the surge. Frontier Airlines and Allegiant up more than 13%, while major airlines like United Airlines, American Airlines, and Delta Air Lines are also up at least 6%. JetBlue and Alaska Air are similarly up about 6%.

The market more broadly is rebounding on Friday, with the S&P 500 up 1.6% and bitcoin recovering some of this week’s losses.

Airlines have been volatile to start 2026 amid geopolitical tensions, varying annual forecasts, and the impact of winter storms.

markets

The AI supply chain is soaring thanks to Amazon’s capex budget

If tech companies are going to spend way more than expected on capex, well, that means other companies are poised to benefit from that massive spending spree.

Amazon’s plan for $200 billion in business investment this year was the exclamation point to end a reporting period that saw every Magnificent 7 hyperscaler that provides guidance offer a 2026 capex budget well above what Wall Street had anticipated.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

markets

For memory chips, the “parabolic price hike” is continuing to ramp higher

The remarkable run-up in prices for memory chips continued into early February, analysts at Bernstein Research say, driven largely by data center demand from hyperscalers and cloud service providers (CSP).

Prices for NAND flash memory wafers — a type of memory used in devices, as it retains data even when powered down — soared 35% between the end of 2025 and February 2.

Spot prices for DRAM — ubiquitous short-term data storage chips — jumped about 28% in that period. But that massively understates the remarkable shift in pricing for what were long seen as commodity tech hardware inputs. DRAM prices are more than 2,000% over the last year, while NAND prices are up more than 600% in that period.

The ongoing momentum provides still more support for memory chip plays like Micron and Sandisk, which have been big market winners in recent months.

In a note published earlier this week, Bernstein Research analysts wrote:

“The parabolic price hike continued in Jan. Indicated price increase for 1QCY26 is much stronger than we expected and we hence see upside to our near term memory pricing projection. Unrelenting CSP demand remained the main driver. PC and Mobile demand hasn’t been destroyed yet because of lean inventory & pull-forward purchase. Going forward price hike is expected to continue but likely at a slower rate, as PC and Mobile demand should contract meaningfully this year. Price however may stay elevated throughout this year, supported by CSP demand.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.